{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:06:19Z","timestamp":1747800379261,"version":"3.41.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institute for Health and Care Research Birmingham Biomedical Research Centre"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"DOI":"10.1038\/s44276-025-00136-3","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:47:16Z","timestamp":1747734436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stereotactic ablative radiotherapy for patients with hepatocellular carcinoma: analysis of post-treatment radiology and explant histology"],"prefix":"10.1038","volume":"3","author":[{"given":"Nekisa","family":"Zakeri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramanivas","family":"Sundareyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen","family":"Cain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Good","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahir","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shishir","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"136_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"136_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7:6.","journal-title":"Nat Rev Dis Prim"},{"key":"136_CR3","unstructured":"NHS England. Clinical Commissioning Policy: Stereotactic Ablative Radiotherapy (SABR) for Hepatocellular Carcinoma (Adults) (URN:1913) [200206P]."},{"key":"136_CR4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/jgh.15175","volume":"36","author":"MD Shanker","year":"2021","unstructured":"Shanker MD, Liu HY, Lee YY, Stuart KA, Powell EE, Wigg A, et al. Stereotactic radiotherapy for hepatocellular carcinoma: expanding the multidisciplinary armamentarium. J Gastroenterol Hepatol. 2021;36:873\u201384.","journal-title":"J Gastroenterol Hepatol"},{"key":"136_CR5","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1080\/0284186X.2019.1657942","volume":"58","author":"M Dobrzycka","year":"2019","unstructured":"Dobrzycka M, Spychalski P, Rostkowska O, Wilczynski M, Kobiela P, Grat M, et al. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma \u2013 a systematic review on outcome. Acta Oncol. 2019;58:1706\u201313.","journal-title":"Acta Oncol"},{"key":"136_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.radonc.2018.12.005","volume":"131","author":"CH Rim","year":"2019","unstructured":"Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Radiother Oncol. 2019;131:135\u201344.","journal-title":"Radiother Oncol"},{"key":"136_CR7","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1002\/cncr.30008","volume":"122","author":"A Takeda","year":"2016","unstructured":"Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. 2016;122:2041\u20139.","journal-title":"Cancer"},{"key":"136_CR8","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1002\/cncr.27533","volume":"118","author":"JK Kang","year":"2012","unstructured":"Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012;118:5424\u201331.","journal-title":"Cancer"},{"key":"136_CR9","doi-asserted-by":"publisher","first-page":"40756","DOI":"10.18632\/oncotarget.9450","volume":"7","author":"JW Kim","year":"2016","unstructured":"Kim JW, Seong J, Lee IJ, Woo JY, Han KH. Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma. Oncotarget. 2016;7:40756.","journal-title":"Oncotarget"},{"key":"136_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","volume":"67","author":"G Sapisochin","year":"2017","unstructured":"Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67:92\u201399.","journal-title":"J Hepatol"},{"key":"136_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1200\/jco.2016.34.4_suppl.418","volume":"34","author":"AS Barry","year":"2016","unstructured":"Barry AS, Sapisochin G, Russo M, Brade AM, Brierley JD, Kim JH, et al. The use of stereotactic body radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. J Clin Oncol. 2016;34:418.","journal-title":"J Clin Oncol"},{"key":"136_CR12","doi-asserted-by":"crossref","unstructured":"Nugent FW, Qamar A, Stuart KE, Galuski K, Flacke S, Molgaard C, et al. A randomized phase II feasibility study of individualized stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) with DEBDOX beads as a bridge to transplant in hepatocellular carcinoma (HCC). J Clin Oncol. 2017;35.","DOI":"10.1200\/JCO.2017.35.4_suppl.223"},{"key":"136_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182\u20138.","journal-title":"Histopathology"},{"key":"136_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver.","year":"2018","unstructured":"European Association for the Study of the Liver. EASl clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"136_CR15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723\u201350.","journal-title":"Hepatology"},{"key":"136_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"136_CR17","first-page":"421","volume":"35","author":"J Bruix","year":"2001","unstructured":"Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. Eur Assoc Study Liver J Hepatol. 2001;35:421\u201330.","journal-title":"Eur Assoc Study Liver J Hepatol"},{"key":"136_CR18","doi-asserted-by":"publisher","first-page":"e0133488","DOI":"10.1371\/journal.pone.0133488","volume":"10","author":"B Vincenzi","year":"2015","unstructured":"Vincenzi B, Di Maio M, Silletta M, D\u2019Onofrio L, Spoto C, Piccirillo MC, et al. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS One. 2015;10:e0133488.","journal-title":"PLoS One"},{"key":"136_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.cgh.2017.11.037","volume":"16","author":"N Mehta","year":"2018","unstructured":"Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, et al. Excellent outcomes of liver transplantation following down staging of hepatocellular carcinoma to within milan criteria: a multi-center study. Clin Gastroenterol Hepatol. 2018;16:955\u201364.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"136_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/jso.22104","volume":"105","author":"ME Facciuto","year":"2012","unstructured":"Facciuto ME, Singh MK, Rochon C, Sharma J, Gimenez C, Katta U, et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol. 2012;105:692\u20138.","journal-title":"J Surg Oncol"},{"key":"136_CR21","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.3748\/wjg.v27.i24.3630","volume":"27","author":"U Bauer","year":"2021","unstructured":"Bauer U, Gerum S, Roeder F, Munch S, Combs SE, Philipp AB, et al. High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy. World J Gastroenterol. 2021;27:3630\u201342.","journal-title":"World J Gastroenterol"},{"key":"136_CR22","doi-asserted-by":"crossref","unstructured":"Mohamed M, Katz AW, Tejani MA, Sharma AK, Kashyap R, Noel MS, et al. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Adv Radiat Oncol. 29;1:35-42.","DOI":"10.1016\/j.adro.2015.12.003"},{"key":"136_CR23","doi-asserted-by":"crossref","unstructured":"Goyal K, Einstein D, Yao M, Kunos C, Barton F, Singh D, et al. Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: preliminary results. HPB Surg 2010;309780.","DOI":"10.1155\/2010\/309780"},{"key":"136_CR24","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/s41416-021-01535-2","volume":"125","author":"A Childs","year":"2021","unstructured":"Childs A, Zakeri N, Ma YT, O\u2019Rourke J, Ross P, Hashem E, et al. Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. Br J Cancer. 2021;125:1350\u20135.","journal-title":"Br J Cancer"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00136-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00136-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00136-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:47:19Z","timestamp":1747734439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00136-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["136"],"URL":"https:\/\/doi.org\/10.1038\/s44276-025-00136-3","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The study was approved by the Institutional Review Board of the Queen Elizabeth Hospital Birmingham UK (Clinical audit registration and management system reference number 22814). Participants\u2019 consent was not required for approval as presented data are all anonymised.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"36"}}